BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 23174198)

  • 1. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
    Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
    Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
    Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
    Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.
    Li J; Yu T; Wang X; Zhou J; Gao R; Zhang F; Gao X; Gao S; Liu X
    Virol J; 2015 Jul; 12():113. PubMed ID: 26220290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs.
    Beach NM; Ramamoorthy S; Opriessnig T; Wu SQ; Meng XJ
    Vaccine; 2010 Dec; 29(2):221-32. PubMed ID: 21044670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.
    Opriessnig T; Shen HG; Pal N; Ramamoorthy S; Huang YW; Lager KM; Beach NM; Halbur PG; Meng XJ
    Clin Vaccine Immunol; 2011 Aug; 18(8):1261-8. PubMed ID: 21653745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233.
    Li J; Yu T; Zhang F; Wang X; Zhou J; Gao X; Gao S; Liu X
    Arch Virol; 2017 Jan; 162(1):235-246. PubMed ID: 27722993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2.
    Opriessnig T; Gerber PF; Xiao CT; Halbur PG; Matzinger SR; Meng XJ
    Vaccine; 2014 Jul; 32(34):4342-8. PubMed ID: 24929119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs.
    Fenaux M; Opriessnig T; Halbur PG; Elvinger F; Meng XJ
    J Virol; 2004 Jun; 78(12):6297-303. PubMed ID: 15163723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
    Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
    Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge.
    Opriessnig T; Karuppannan AK; Halbur PG; Calvert JG; Nitzel GP; Matzinger SR; Meng XJ
    Vaccine; 2020 Feb; 38(8):1975-1981. PubMed ID: 31974016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge.
    Park KH; Oh T; Yang S; Cho H; Kang I; Chae C
    Vet Microbiol; 2019 Apr; 231():87-92. PubMed ID: 30955830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain.
    Opriessnig T; Gerber PF; Xiao CT; Mogler M; Halbur PG
    Vaccine; 2014 Jan; 32(2):230-7. PubMed ID: 24269319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV).
    Shen HG; Beach NM; Huang YW; Halbur PG; Meng XJ; Opriessnig T
    Vaccine; 2010 Aug; 28(37):5960-6. PubMed ID: 20637768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of antigenic epitopes of porcine reproductive and respiratory syndrome virus (PRRSV) in a modified live-attenuated porcine circovirus type 2 (PCV2) vaccine virus (PCV1-2a) as a potential bivalent vaccine against both PCV2 and PRRSV.
    Piñeyro PE; Kenney SP; Giménez-Lirola LG; Heffron CL; Matzinger SR; Opriessnig T; Meng XJ
    Virus Res; 2015 Dec; 210():154-64. PubMed ID: 26239318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
    Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
    Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of porcine parvovirus vaccination on the development of PMWS in segregated early weaned pigs coinfected with type 2 porcine circovirus and porcine parvovirus.
    Opriessnig T; Fenaux M; Yu S; Evans RB; Cavanaugh D; Gallup JM; Pallares FJ; Thacker EL; Lager KM; Meng XJ; Halbur PG
    Vet Microbiol; 2004 Mar; 98(3-4):209-20. PubMed ID: 15036529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
    Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
    Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA.
    Shen HG; Halbur PG; Opriessnig T
    J Gen Virol; 2012 Jun; 93(Pt 6):1345-1355. PubMed ID: 22398315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Porcine reproductive and respiratory syndrome virus (PRRSV) influences infection dynamics of porcine circovirus type 2 (PCV2) subtypes PCV2a and PCV2b by prolonging PCV2 viremia and shedding.
    Sinha A; Shen HG; Schalk S; Beach NM; Huang YW; Meng XJ; Halbur PG; Opriessnig T
    Vet Microbiol; 2011 Sep; 152(3-4):235-46. PubMed ID: 21641124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b.
    Jeong J; Park C; Choi K; Chae C
    Vet Microbiol; 2015 May; 177(1-2):43-52. PubMed ID: 25790733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.